Jubilant Pharmova to sell, transfer API business to wholly owned arm
Advertisement
Noida: Jubilant Pharmova Limited announced the sale and transfer of its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary company, Jubilant Biosys Limited, on a slump sale basis.
The API business will be transferred with effect from September 1, 2025, subject to customary approvals from lenders & Shareholders of the company. The transaction is at arm’s length as there is no change in the economic interest of the shareholders of the company.
The Active Pharmaceutical Ingredients business of the Company achieved a Turnover of Rs. 609 crores, representing 8.35% of the consolidated turnover of the Company for the financial year ended March 31, 2025. The Networth of the Active Pharmaceutical business under transfer is Rs. 666.5 crores which represents 10.68% of the consolidated Networth of the Company as at March 31,2025.
The Purchase consideration to be discharged by transferee company shall be determined based on the book value of assets and liabilities as of appointed date of business transfer basis Rule 11UAE prescribed by the Income Tax Rules’ 1962. The consideration so determined & payable by the transferee entity shall be discharged primarily by issuance of shares as provided in the Business Transfer Agreement.
The transaction will result in housing of the drug discovery business and CDMO API business in a single business entity. This combined platform will improve the operational efficiency in the business and lead to superior brand recall of “Jubilant Biosys” as provider of end-to-end CRDMO (Drug discovery, Early CDMO, late CDMO and commercial manufacturing) services by the large pharmaceutical & Biotech customers. The transaction will also help to improve asset utilisation of API business.
"As both entities are part of the same corporate group, the transaction is primarily intended to support operational efficiency and strategic alignment and is not intended to confer any undue benefit to either party," the company stated in a recent BSE filing.
The company's Vision 2030 for this business is to grow the revenues to 2x from FY24 levels and improve EBITDA margins to more than 15%.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.